Trials / Conditions / Refractory Acute Biphenotypic Leukemia
Refractory Acute Biphenotypic Leukemia
4 registered clinical trials studyying Refractory Acute Biphenotypic Leukemia — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms NCT04797767 | University of Washington | Phase 1 / Phase 2 |
| Terminated | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplast NCT04874194 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute M NCT04975919 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia NCT04526795 | M.D. Anderson Cancer Center | Phase 1 |